NCT06385678View on ClinicalTrials.gov

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Advanced KRAS G12D Mutant Solid Tumors
Interventions
DRUG

HRS-4642

administrated per dose level in which the patients are assigned

DRUG

Adebrelimab

administrated per dose level in which the patients are assigned

DRUG

SHR-9839

administrated per dose level in which the patients are assigned

DRUG

Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection

administered as prescribed by the investigator.

DRUG

Cetuximab Solution for Infusion

administrated per dose level in which the patients are assigned

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06385678 - A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Biotech Hunter | Biotech Hunter